文献速递甲状腺核医学核素与放射性配体治疗

分子标志物与甲状腺乳头状癌患者放射性碘难治性发生相关

Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
PubMed 文献 · J Nucl Med · 2023-12-01

该研究纳入38例甲状腺全切除术后接受放射性碘成像和18F-FDG PET/CT的甲状腺乳头状癌患者,通过二代测序评估分子谱,比较不同基因改变与放射性碘难治性甲状腺癌(RR-TC)发生时间的关系。结果显示端粒酶逆转录酶启动子突变和肿瘤蛋白53突变与RR-TC发生显著相关,而BRAFV600E突变未见此关联。

要点

  • 端粒酶逆转录酶启动子突变患者RR-TC中位发生时间为0.7个月,无突变者为19.8个月(P=0.02)。
  • 肿瘤蛋白53突变患者RR-TC中位发生时间为1.7个月,无突变者为19.8个月(P<0.01)。
  • BRAFV600E突变与RR-TC发生未见显著关联(P=0.49)。

核心结论

  • 数据表明RR-TC发生与端粒酶逆转录酶启动子突变和肿瘤蛋白53突变显著相关,提示这些患者需要更广泛的诊断检查。

研究设计与样本

  • 研究纳入38例甲状腺乳头状癌患者,均为甲状腺全切除术后接受放射性碘成像和18F-FDG PET/CT者,分子谱通过二代测序评估,不同基因改变的RR-TC发生时间采用对数秩检验比较。

主要发现

  • 有端粒酶逆转录酶启动子突变患者RR-TC中位发生时间为0.7个月,无该突变者为19.8个月(P=0.02)。
  • 有肿瘤蛋白53突变患者RR-TC中位发生时间为1.7个月,无该突变者为19.8个月(P<0.01)。
  • BRAFV600E突变与RR-TC发生无显著关联(P=0.49)。

临床怎么用

  • 作者认为端粒酶逆转录酶启动子突变和肿瘤蛋白53突变与RR-TC发生显著相关,提示这些患者需要更广泛的诊断检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The onset of radioiodine-refractory thyroid carcinoma (RR-TC) is a negative predictor of survival and has been linked to the presence of BRAFV600E mutations in papillary thyroid cancer. We aimed to identify further genetic alterations associated with RR-TC. Methods: We included 38 patients with papillary thyroid cancer who underwent radioiodine imaging and 18F-FDG PET/CT after total thyroidectomy. The molecular profile was assessed by next-generation sequencing. The time to the onset of RR-TC for different genetic alterations was compared using the log-rank test. Results: The median onset to RR-TC was 0.7 and 19.8 mo in patients with and without, respectively, telomerase reverse transcriptase promoter mutations (P = 0.02) and 1.7 and 19.8 mo in patients with and without, respectively, a tumor protein 53 mutation (P < 0.01). This association was not observed for BRAFV600E mutations (P = 0.49). Conclusion: Our data show a significant association between the onset of RR-TC and mutations in telomerase reverse transcriptase promoter and tumor protein 53, indicating the need for a more extensive diagnostic workup in these patients. Certain genetic changes put patients with thyroid cancer at risk of developing cancer spread that does not respond to radioiodine therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Laschinsky C, Theurer S, Herold T, et al. Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma. J Nucl Med. 2023. PMID: 37884333. doi:10.2967/jnumed.123.266044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。